MTOR and familial pancreatic carcinoma: These results indicate that insulin promotes Akt and p-Akt expression, whereas CVM-A potently downregulates these proteins, suggesting its potential as a therapeutic agent targeting the PI3K/Akt/mTOR pathway in the pancreatic cancer microenvironment.